• • Correction of Figure 1g (MIC determination) ensures accurate reporting of LS5 activity against E. coli, S. aureus, and P. aeruginosa; precise MIC values are critical for clinical dose selection and regulatory submission, as underestimation can lead to subtherapeutic dosing and resistance emergence.
• • Correction of Figure 3b (blood cell SEM and microscopic observation) rectifies the assessment of hemocompatibility; accurate morphological data are essential for predicting infusion-related toxicity and for meeting ISO 10993-4 hemolysis thresholds (e.g., <5% hemolysis) in preclinical safety packages.
• • Correction of Figure 4a (wound healing rate assay) restores the quantitative healing kinetics; erroneous image placement could misrepresent the pro-healing efficacy of LS5-gel, impacting decisions on formulation optimization and clinical trial design for chronic wound indications.
• • All statistical comparisons in the biocompatibility studies (Figure 3) report p < 0.05, confirming that LS5 and LS5-gel do not significantly compromise cell viability, migration, or blood compatibility relative to controls; this supports the peptide's safety margin for systemic administration in sepsis therapy.